Global Psychedelic therapeutics market is projected to grow at an annualized rate of ~15%, till 2030

Roots Analysis has done a detailed study on  “Global Psychedelic TherapeuticsMarket, 2020-2030”, covering keyaspects of the industry and identifying potential future growth opportunities

To order this 250+ page report, which features 120+ figuresand 135+ tables, please visit this link  

Key Market Insights

§ Nearly 70 players from across the world presently claim tobe engaged in the development and evaluation of therapeutic candidates based ona number of psychedelic compounds, such as ketamine and psilocybin

§ The pipeline features product candidates based on a varietyof psychedelic drug classes, which are being investigated for a wide range oftarget disease indications, and having different routes of administration

§ From a global perspective, this industry is anticipated toevolve significantly over the next few years as federal / regional regulatorsin different nations are gradually convinced of the clinical significance ofthis product class

§ Several organizations, having realized the untappedopportunity within this emerging segment of psychedelic therapeutics, haveawarded grants of over USD 275 million across 500+ instances between 2015-2020

§ Several trials evaluating variouspsychedelic compounds against a wide range of therapeutic indication have beenregistered in the recent past

§ The growing interest is also reflected in the partnershipactivity since 2017; a number of different types of deals involving variousdrug classes have been established across multiple geographies

§ Presently, North American companies are activelyconsolidating their indigenous presence through strategic acquisitions; keyvalue drivers behind such deals include both portfolio and geographicalexpansion

§ A number of eminent scientists from renowned universitieshave emerged as key opinion leaders in this domain, owing to their activeinvolvement in clinical development efforts related to interventions based onpsychedelics

§ Future market size, based on revenue reported from thesales of marketed and late stage psychedelic-based  therapies, is anticipated to be distributedacross different therapeutic areas and key geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

Table of Contents

1.                     PREFACE

1.1.                   Scope of the Report

1.2.                   Research Methodology

1.3.                   Chapter Outlines

2.                     EXECUTIVE SUMMARY

3.                     INTRODUCTION

3.1.                   Chapter Overview

3.2.                   History of Psychedelic Substance

3.3.                   Potential Therapeutic Application ofPsychedelic Substance

3.4.                   Regulation,Toxicity Concerns, Procurement-Related Challenges and Perceptions RegardingMedical Use

3.5.                   Future Opportunity

4.                     MARKET LANDSCAPE: PSYCHEDELICTHERAPEUTICS

4.1.                   Chapter Overview

4.2.                   Psychedelic Therapeutics: Marketedand Development Pipeline

4.2.1.                Analysis by Phase of Development

4.2.2.                Analysis by Type of PsychedelicSubstance

4.2.3.                Analysis by Origin of PsychedelicSubstance

4.2.4.                Analysis by Target Therapeutic Area

4.2.5.                Analysis by Type of Therapy

4.2.6.                Analysis by Route of Administration

4.2.7.                Analysis by Dosing Frequency

4.3.                   Psychedelic Therapeutics: List ofDevelopers

4.3.1.                Analysis by Year of Establishment

4.3.2.                Analysis by Company Size

4. 3.3.               Analysis by Location of Headquarters

4.4.                   GridAnalysis: Distribution by Phase of Development, Origin of Psychedelic Substanceand Location of Headquarters

5.                     COMPANY PROFILES

5.1.                   Chapter Overview

5.2.                   Celon Pharma

5.2.1.                Company Overview

5.2.2.                Financial Information

5.2.3.                Psychedelic Therapeutics Portfolio

5.2.3.1.             Esketamine DPI

5.2.4.                Recent Developments and FutureOutlook

5.3.                   iX Biopharma

5.3.1.                Company Overview

5.3.2.                Financial Information

5.3.3.                Psychedelic Therapeutics Portfolio

5.3.3.1.             Wafermine™

5.3.3.2.             Unnamed (Ketamine)

5.3.4.                Recent Developments and FutureOutlook

5.4.                   MAPS Public Benefit

5.4.1.                Company Overview

5.4.2.                Financial Information

5.4.3.                Psychedelic Therapeutics Portfolio

5.4.3.1.             Unnamed (MDMA)

5.4.3.2.             Unnamed (Ibogaine Hydrochloride)

5.4.3.3.             Unnamed (LSD)

5.4.3.4.             Unnamed (Ayahuasca)

5.4.4.                Recent Developments and FutureOutlook

5.5.                   MindMed

5.5.1.                Company Overview

5.5.2.                Psychedelic Therapeutics Portfolio

5.5.2.1.             Unnamed (LSD)

5.5.2.2.             Unnamed (MDMA)

5.5.2.3.             18-MC

5.5.2.4.             Unnamed (DMT)

5.5.2.5.             Unnamed (LSD, MDMA)

5.5.3.                Recent Developments and FutureOutlook

5.6.                   Janssen Pharmaceuticals

5.6.1.                Company Overview

5.6.2.                Financial Information

5.6.3.                Psychedelic Therapeutics Portfolio

5.6.3.1.             SPRAVATO®

5.6.4.                Recent Developments and FutureOutlook

5.7.                   Jazz Pharmaceutical

5.7.1.                Company Overview

5.7.2.                Financial Information

5.7.3.                Psychedelic Therapeutics Portfolio

5.7.3.1.             XYREM®

5.7.3.2.             JZP-258

5.7.3.3.             JZP-324

5.7.4.                Recent Developments and FutureOutlook

6.                     CLINICAL TRIAL ANALYSIS

6.1.                   Chapter Overview

6.2.                   Scope and Methodology

6.3.                   Psychedelic Therapeutics: Clinical TrialAnalysis

6.3.1.                Analysis by Trial Registration Year

6.3.2.                Analysis by Trial Phase

6.3.3.                Analysis by Trial Recruitment Status

6.3.4.                Analysis by Trial Registration Yearand Number of Patients Enrolled

6.3.5.                Analysis by Study Design

6.3.6.                Leading Trial Sponsors: Analysis byNumber of Registered Trials

6.3.7.                Leading Players: Analysis by Numberof Registered Trials

6.3.8.                Analysis by Trial Focus

6.3.9.                Analysis by Target Therapeutic Area

6.3.10.             Popular Psychedelic Substance:Analysis by Number of Registered Trials

6.3.11.             Geographical Analysis by Number ofRegistered Trials

6.3.12.             GeographicalAnalysis by Number of Patients Enrolled

7.                     CLINICAL TRIAL SITE ANALYSIS

7.1.                   Chapter Overview

7.2.                   Scope and Methodology

7.3.                   Psychedelic Therapeutics: ClinicalTrial Site Analysis

7.3.1.                Analysis by Geographical Location

7.3.1.1.             Clinical Trial Sites in NorthAmerica

7.3.1.1.1.          Analysisby Trial Phase

7.3.1.1.2.          Analysisby Target Therapeutic Area

7.3.1.1.2.          Analysisby Trial Phase and Target Therapeutic Area

7.3.1.2.             Clinical Trial Sites in Europe

7.3.1.2.1.          Analysisby Trial Phase

7.3.1.2.2.          Analysisby Target Therapeutic Area

7.3.1.2.2.          Analysisby Trial Phase and Target Therapeutic Area

7.3.1.3.             Clinical Trial Sites in Asia Pacific

7.3.1.3.1.          Analysisby Trial Phase

7.3.1.3.2.          Analysisby Target Therapeutic Area

7.3.1.3.2.          Analysisby Trial Phase and Target Therapeutic Area

8.                     KEY OPINION LEADER (KOL) ANALYSIS

8.1.                   Chapter Overview

8.2.                   Assumptions and Methodology

8.3.                   Principal Investigators Involved inClinical Trials

8.3.1.                Analysis by Type of Organization(KOL Affiliation)

8.3.2.                Geographical Distribution of KOLs

8.4.                   Prominent KOLs

8.5.                   KOLBenchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGateScore)

8.6.                   Most Active KOLs

8.6.1.                KOL Profile: A (Emory School ofMedicine)

8.6.2.                KOL Profile: B (Imperial CollegeLondon)

8.6.3.                KOL Profile: C (Rigshospitalet)

8.6.4.                KOL Profile: D (Thriving Mind South Florida)

8.6.5.                KOL Profile: E (University HealthNetwork)

9.                     ACADEMIC GRANTS ANALYSIS

9.1.                   Chapter Overview

9.2.                   Scope and Methodology

9.3.                   Psychedelic Therapeutics: Analysisof Academic Grants

9.3.1.                Analysis by Year of Grant Award

9.3.2.                Analysis by Amount Awarded

9.3.3.                Analysis by Funding Institute Center

9.3.4.                Analysis by Support Period

9.3.5.                Analysis by Funding Institute Centerand Support Period

9.3.6.                Analysis by Type of GrantApplication

9.3.7.                Analysis by Purpose of Grant Award

9.3.8.                Analysis by Activity Code

9.3.9.                Analysis by Study Section Involved

9.3.10.              Analysis by Recipient Organization

9.3.11.              Geographical Distribution ofRecipient Organizations

9.3.12.              Word Cloud: Emerging Focus Areas

9.3.13.              Popular Psychedelic Therapeutics:Analysis by Number of Grants

9.3.14.              Popular Funding Institute Centers:Analysis by Number of Grants

9.3.15.              Prominent Program Officers: Analysisby Number of Grants

9.3.16.              Popular Recipient Organizations:Analysis by Number of Grants

10.                    PARTNERSHIPS AND COLLABORATIONS

10.1.                 Chapter Overview

10.2.                 Partnership Models

10.3.                 Psychedelic Therapeutics: List ofPartnerships and Collaborations

10.3.1.             Analysis by Year of Partnership

10.3.2.             Analysis by Type of Partnership

10.3.3.             Analysis by Type of Partnership andType of Psychedelic Substance Involved

10.3.4.              Analysisby Type of Partnership and Phase of Development of Involved Intervention

10.3.5.               Analysisby Type of Partnership and Target Therapeutic Area Mentioned

10.3.6.             Analysis by Type of PsychedelicSubstance and Target Therapeutic Area

10.3.7.             Analysis by Type of Partnership andType of Partner

10.3.8.             Analysis by Type of PsychedelicSubstance Involved and Type of Partner

10.3.9.             Most Active Players: Analysis byNumber of Partnerships

10.3.10.            RegionalAnalysis

10.3.10.1          Intercontinentaland Intracontinental Agreements

11.                    MERGERS AND ACQUISITIONS

11.1.                 Chapter Overview

11.2.                 Acquisition Models

11.3.                 Psychedelic Therapeutics: Mergersand Acquisitions

11.3.1.             Cumulative Year-wise Trend ofMergers and Acquisitions

11.3.2.             Analysis by Type of Agreement

11.3.3.             Analysis by Type of PsychedelicSubstance Involved

11.3.4.             Analysis by Type of Agreement andType of Psychedelic Substance Involved

11.3.5.             Most Active Players: Analysis byNumber of Acquisitions

11.3.6.             Regional Analysis

11.3.6.1.           Continent-WiseDistribution of Acquisitions

11.3.6.2.           Country-WiseDistribution of Acquisitions

11.3.7.             Analysis by Key Value Drivers

11.3.7.1.           Analysisby Year of Acquisition and Key Value Drivers

12.                    MARKET FORECAST AND OPPORTUNITYANALYSIS

12.1.                 Chapter Overview

12.2.                 Forecast Methodology and KeyAssumptions

12.3.                 Global Psychedelic TherapeuticsMarket, 2020-2030

12.4.                 Global Psychedelic TherapeuticsMarket: Individual Product Sales Forecasts

12.4.1.              Xyrem (Jazz Pharmaceutical)

12.4.1.1.           TargetPatient Population

12.4.1.2.           SalesForecast

12.4.2.              Spravato (Janssen Pharmaceuticals)

12.4.2.1.           TargetPatient Population

12.4.2.2.           SalesForecast

12.4.3.              JPZ-258 (Janssen Pharmaceuticals)

12.4.3.1.           TargetPatient Population

12.4.3.2.           SalesForecast

12.4.4.              FT218 (Avadel Pharmaceuticals)

12.4.4.1.           TargetPatient Population

12.4.4.2.           SalesForecast

12.4.5.              Unnamed MDMA (MAPS Public Benefit)

12.4.5.1.           TargetPatient Population

12.4.5.2.           SalesForecast

12.4.6.              COMP360 (COMPASS Pathways)

12.4.6.1.           TargetPatient Population

12.4.6.2.           SalesForecast

12.4.7.              Unnamed Psilocybin (The EmmesCompany)

12.4.7.1.           TargetPatient Population

12.4.7.2.           SalesForecast

12.4.8.              Esketamine DPI (Celon Pharma)

12.4.8.1.           TargetPatient Population

12.4.8.2.           SalesForecast

12.4.9.              Wafermine (iX Biopharma)

12.4.9.1.           TargetPatient Population

12.4.9.2.           SalesForecast

12.5.                 GlobalPsychedelic Therapeutics Market: Distribution by Origin of PsychedelicSubstance, 2020-2030

12.5.1.              Global Psychedelic TherapeuticsMarket for Synthetic Substances, 2020-2030

12.5.2.              Global Psychedelic Therapeutics Marketfor Natural Substances, 2020-2030

12.6.                 GlobalPsychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance,2025-2030

12.6.1.              Global Psychedelic TherapeuticsMarket for GHB, 2020-2030

12.6.2.              Global Psychedelic Therapeutics Marketfor Ketamine, 2020-2030

12.6.3.              Global Psychedelic TherapeuticsMarket for MDMA, 2021-2030

12.6.4.              Global Psychedelic TherapeuticsMarket for Psilocybin, 2023-2030

12.7.                 Global Psychedelic TherapeuticsMarket: Distribution by Geography, 2020-2030

12.7.1.              Global Psychedelic TherapeuticsMarket in North America, 2020-2030

12.7.2.              Global Psychedelic TherapeuticsMarket in Europe, 2020-2030

12.7.3.              Global Psychedelic TherapeuticsMarket in Asia Pacific, 2022-2030

12.8.                 GlobalPsychedelic Therapeutics Market: Distribution by Target Therapeutic Area,2020-2030

12.8.1.              Global Psychedelic TherapeuticsMarket for Sleep-Related Disorders, 2020-2030

12.8.2.              GlobalPsychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030

12.8.3.              Global Psychedelic TherapeuticsMarket for Trauma, 2021-2030

12.8.4.              Global Psychedelic TherapeuticsMarket for Pain Disorders, 2026-2030

12.9.                 GlobalPsychedelic Therapeutics Market: Distribution by Route of Administration,2020-2030

12.9.1.              Global Psychedelic TherapeuticsMarket for Oral Therapies, 2020-2030

12.9.2.              Global Psychedelic TherapeuticsMarket for Intranasal Therapies, 2020-2030

12.9.3.              Global Psychedelic TherapeuticsMarket for Sublingual Therapies, 2026-2030

13.                    CONCLUDING REMARKS

13.1.                 Chapter Overview

13.2.                 Key Takeaways

14.                    EXECUTIVE INSIGHTS

14.1.                 Chapter Overview

14.2                   CaaMTech                   

14.2.1.              Company Snapshot

14.2.2.              InterviewTranscript: Andrew Chadeayne, Founder & Chief Executive Officer

14.3.                 iXBiopharma

14.3.1.              CompanySnapshot

14.3.2.              InterviewTranscript: Janakan Krishnarajah, Chief Operating Officer and Chief MedicalOfficer

14.4                   OrthogonalThinkers

14.4.1.              CompanySnapshot

14.4.2.              InterviewTranscript: Tracy Cheung, Alexander Speiser, Chief Operating Officer

14.5                   COMPASSPathways

14.5.1.              CompanySnapshot

14.5.2.              InterviewTranscript: Tracy Cheung, Chief Communications Officer

14.7                   YaleUniversity

14.7.1.              CompanySnapshot

14.7.2.              InterviewTranscript: Benjamin Kelmendi, Assistant Professor of Psychiatry

15.        APPENDIX 1: TABULATED DATA

16.        APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415